.png){kind=spacer}
Preparation And Storage
Product Notices
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- An isotype control should be used at the same concentration as the antibody of interest.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
Companion Products
.png?imwidth=320)
The AFS98 monoclonal antibody specifically recognizes CD115 which is also known as Colony stimulating factor 1 Receptor (CSF-1R), Macrophage colony-stimulating factor 1 receptor (M-CSFR), or c-fms. This type I transmembrane glycoprotein is a receptor tyrosine kinase (RTK) that is encoded by Csf1r which belongs to the Ig superfamily. CD115 (CSF-1R) is comprised of an extracellular ligand-binding domain that is followed by a single transmembrane segment and a split intracellular tyrosine kinase domain. This receptor is expressed on monocytes, macrophages, dendritic cells, osteoclasts, and their precursors. Colony-stimulating factor 1 (CSF-1), also known as Macrophage colony-stimulating factor (M-CSF), binds to and signals through CD115 (CSF-1R) homodimers which undergo tyrosine autophosphorylation. The activated receptors transduce intracellular signals resulting in cytoskeletal reorganization and gene expression involved in the proliferation, differentiation, and survival of CSF-1-responding cells. Through CD115 (CSF-1R), CSF-1 regulates the release of proinflammatory cytokines and other mediators from macrophages and plays a role in the bone resorption activity of osteoclasts. Interleukin-34 (IL-34) is another ligand for CD115 (CSF-1R) that can induce similar, as well as, some different biological responses by target cells that express this receptor.
Development References (5)
-
Fend L, Accart N, Kintz J et al. Therapeutic effects of anti-CD115 monoclonal antibody in mouse cancer models through dual inhibition of tumor-associated macrophages and osteoclasts. PLoS ONE. 2013; 8(9):e73310. (Clone-specific: Blocking). View Reference
-
Jose MD, Le Meur Y, Atkins RC, Chadban SJ. Blockade of macrophage colony-stimulating factor reduces macrophage proliferation and accumulation in renal allograft rejection.. Am J Transplant. 2003; 3(3):294-300. (Clone-specific: Blocking, Immunohistochemistry, Inhibition). View Reference
-
Murayama T, Yokode M, Kataoka H, et al. Intraperitoneal administration of anti-c-fms monoclonal antibody prevents initial events of atherogenesis but does not reduce the size of advanced lesions in apolipoprotein E-deficient mice.. Circulation. 1999; 99(13):1740-6. (Clone-specific: Flow cytometry, In vivo exacerbation). View Reference
-
Rothwell VM, Rohrschneider LR. Murine c-fms cDNA: cloning, sequence analysis and retroviral expression. Oncogene Res. 1987; 1(4):311-324. (Biology). View Reference
-
Sudo T, Nishikawa S, Ogawa M, et al. Functional hierarchy of c-kit and c-fms in intramarrow production of CFU-M.. Oncogene. 1995; 11(12):2469-76. (Immunogen: Blocking, Flow cytometry, Fluorescence activated cell sorting, Functional assay, Immunoprecipitation, Inhibition, In vivo exacerbation, Radioimmunoassay). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
